Cerebrolysin

Cerebrolysin, also known as FPE 1070, is a neuropeptide mixture obtained from porcine brain tissue. Its neurotrophic fractions include fragments resembling BDNF, NGF, CNTF and GDNF, with sizes below 10 kDa.

Austria, Russia, China, South Korea and other countries have approved it for Alzheimer’s disease, recovery after stroke and traumatic brain injury. Several randomized controlled studies have found improvements in cognition and function. It has no FDA approval in the United States.

• Cognitive Function

  Effective

  Cognitive research examines possible improvements in memory, attention and information processing.

• Neuroprotection

  Moderate

  Potential neuronal protection includes limiting damage caused by oxidative stress and inflammation.

• Mood & Anxiety

  Moderate

  Some studies investigate reduced anxiety and more stable mood.

• Stimulants (Modafinil, Adderall)

  Caution

• MAOIs / SSRIs

  Monitor

• Racetams

  Caution

• NAD+

  Compatible

• BPC-157

  Compatible

Diluent: Use bacteriostatic water only; avoid saline because it may cause precipitation.

1. Take the Cerebrolysin vial out of the refrigerator and leave it for 15–20 minutes to reach room temperature.
2. Disinfect the vial stopper with an alcohol swab. Wait until the alcohol has completely air-dried.
3. Measure the calculated amount of bacteriostatic water into a sterile syringe. Use only bacteriostatic water; avoid saline because precipitation may occur.
4. Add the water slowly along the inner wall of the vial. Keep the stream away from the powder itself.
5. Rotate the vial gently to mix its contents. Never shake it vigorously, because this can degrade the peptide.
6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is clear and has no color.
7. Withdraw the calculated dose into an insulin syringe for administration beneath the skin.
8. Inject into your abdomen, thigh or upper arm. Change the injection site each time to help prevent lipodystrophy.
9. Refrigerate the mixed solution at 2–8 °C. Use it within 28 days after reconstitution.

Week 1–2

Small improvements in mood and attention may emerge, with better sleep appearing early.

Week 2–4

Possible changes include clearer thinking, easier word retrieval and less brain fog.

Week 4–8

Cognitive changes may become more consistent, alongside improved working memory and responses to stress.

Week 8+

Cognitive and neurological effects may continue and can potentially last beyond the end of a cycle. These intervals are research expectations, not established individual outcomes.

• Headache, especially when beginning use
• Mild restlessness or anxiety with some compounds
• Irritation of the nasal lining after intranasal administration
• Disrupted sleep when dosing near bedtime
• Changes in mood or emotional stability · Rare

Cerebrolysin: not approved in the US.

• US

  Not approved

  FDA — no US approval; approvals in Austria, Russia, China and South Korea cover Alzheimer’s disease, post-stroke recovery and traumatic brain injury.

  Rx required

  No

  503A

  Allowed

  Telehealth

  N/A

• EU

  Approved

  Austria — national approval for Alzheimer’s disease, recovery after stroke and traumatic brain injury; this does not establish EU-wide authorization.

1. Cerebrolysin for acute ischemic stroke (review) (2017)

2. Cerebrolysin for acute ischaemic stroke. (2023)

   PMID 37818733DOI 10.1002/14651858.CD007026.pub7

3. Cerebrolysin for acute ischaemic stroke. (2017)

   PMID 28430363DOI 10.1002/14651858.CD007026.pub5

4. Gauthier S et al. — Cerebrolysin MCI trial (2015) (2015)